Diagnostic Center | September 12, 2022
Merck’s pembrolizumab plus chemotherapy showed sustained survival benefit versus chemotherapy alone
In first-line metastatic NSCLC, KEYTRUDA-based regimens have now shown a five-year survival benefit in four trials